CHEMBIO DIAGNOSTICS INC (CEMI)
US1635722093 - Common Stock
CHEMBIO DIAGNOSTICS INC
NASDAQ:CEMI (4/27/2023, 7:20:06 PM)
After market: 0.4311 -0.02 (-5.25%)0.455
+0 (+0.22%)
Company Profile
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Medford, New York and currently employs 188 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
Company Info
CHEMBIO DIAGNOSTICS INC
555 Wireless Blvd, 3661 Horseblock Road
Medford NEW YORK 11788
P: 16319241135.0
CEO: Richard L. Eberly
Employees: 188
Website: http://chembio.com/
CEMI News
6 months ago - Life Science Outsourcing, Inc.Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer/PRNewswire/ -- Life Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life...
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE...
a year ago - Ademi LLPShareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex/PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex...
STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and...
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
CEMI Twits
Here you can normally see the latest stock twits on CEMI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
